Skip to main content
DrugPrice

Pay-for-Delay Settlement

A patent-litigation settlement in which a brand-name drug manufacturer pays a generic challenger to delay launching its generic version, preserving brand monopoly profits.

How It Works

Pay-for-delay settlements (also called reverse-payment settlements) arise in Hatch-Waxman patent litigation triggered by Paragraph IV ANDA certifications. Under Hatch-Waxman, the first generic to challenge a brand patent earns 180 days of marketing exclusivity, which becomes extremely valuable, often hundreds of millions of dollars on a blockbuster drug. A brand manufacturer facing potential generic entry can settle the patent case by paying the challenger to delay launch, effectively splitting the brand's continued monopoly profits. The Supreme Court addressed pay-for-delay in FTC v. Actavis (2013), holding 5-3 that such settlements can violate antitrust law when the reverse payment is "large and unjustified," applying a rule-of-reason analysis rather than a per-se rule. The FTC has been the lead enforcer: FTC studies estimate pay-for-delay settlements cost U.S. consumers $3.5 billion per year in higher drug prices. Notable post-Actavis enforcement includes the FTC's successful challenge to the Androgel (AbbVie) settlement (resulting in a $448 million consumer redress payment in 2020) and multiple state attorney general actions. Pay-for-delay practice has declined since Actavis but not disappeared; "no-AG" settlements (brand agrees not to launch an authorized generic during the first-filer's 180-day exclusivity) are a modern variant that achieves similar effect without explicit cash payment. Congress has considered per-se prohibitions multiple times (the Preserve Access to Affordable Generics Act), none enacted. Pay-for-delay economics revolve around the value of the residual patent life and the strength of the patent challenge.

Related Terms

  • Abbreviated New Drug Application (ANDA), The FDA application pathway for generic drugs, which requires proving bioequivalence to the brand-name drug rather than repeating full clinical trials.
  • Patent Expiration, The date when a drug's patent protection ends, allowing generic or biosimilar manufacturers to produce competing versions.
  • Skinny Label (Section viii Carve-Out), A generic drug approval strategy under 21 U.S.C. 355(j)(2)(A)(viii) that omits (carves out) patent-protected indications from the generic label, allowing launch before all brand patents expire.
  • Citizen Petition, A formal request filed with the FDA under 21 CFR 10.30 that can be used legitimately or as a delay tactic to slow generic drug approval by raising safety or bioequivalence questions.

Explore Drug Data

Most Expensive DrugsGeneric Drug WatchSearch All Drugs

About This Definition

This definition is part of the DrugPrice Drug Pricing Glossary, 49 terms explaining how prescription drug pricing works in the United States. All definitions are written in plain language for patients, caregivers, journalists, and healthcare professionals.

this entity is one of the U.S. Medicare prescription-drug pricing concepts that recurs across this site. The definition above is the technical answer; the paragraphs below add the practical context for how the concept connects to the CMS Medicare Part D Drug Spending data data behind every per-entity page on the site.

In the CMS Medicare Part D Drug Spending data data, this concept shapes one or more of the fields that drive the per-entity grades and rankings on this site. The methodology page describes which fields feed into which output; this glossary entry documents the underlying term.

Source: CMS Medicare Part D Spending, 2026.